Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

727.21 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements. 
Via MarketBeat
3 Hot Stocks That Have Already Doubled in 2025
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year. 
Via The Motley Fool
Hims & Hers Stock Is On Fire, But Is It a Bubble?
The stock isn't as expensive as you might think. 
Via The Motley Fool
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management. 
Via Benzinga
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent... 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally. 
Via Benzinga
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low? 
Via MarketBeat
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
Via The Motley Fool
MarketBeat Week in Review – 02/10 - 02/14
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in 
Via MarketBeat
Topics Credit Cards Economy Government
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Via The Motley Fool
Behind the Scenes of Eli Lilly's Latest Options Trends
 
Via Benzinga
Top Stock Reports For Apple, Eli Lilly & Shopify
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Eli Lilly and Co., and Shopify Inc., as well as a micro-cap stock ImmuCell Corp. 
Via Talk Markets
Topics Stocks / Equities
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster. 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs. 
Via MarketBeat
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Healthcare And Biotech Playbook As Disruption Gathers Force
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases. 
Via Benzinga
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
Looking Into Eli Lilly's Recent Short Interest
 
Via Benzinga
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system. 
Via Stocktwits
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Via The Motley Fool
How To Ride The Market’s “Great Risk Rollercoaster”
This market is trading in an extremely tight range and has been for a long time now. It’s a market desperate for a catalyst just isn’t finding any - not in data, not in news, not in Tweets. 
Via Talk Markets
Topics ETFs Stocks / Equities
Magnificent Seven Slip, Inflation Fears Grip Consumers, Gold Hits Record Highs: This Week In The Markets
Wall Street cautious on mixed earnings, macroeconomic data, and geopolitical developments. Gold hits record high while Ford's outlook disappoints.Wall St cautious due to mixed earnings, data &... 
Via Benzinga
Topics Economy
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Shares rocketed on Friday, but the company might not be out of hot water yet. 
Via Investor's Business Daily
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.